Info

🌱 來自: Stage II-of-Preoperative Chemotherapy for Operable Breast Cancer

Pertuzumab

(Perjeta)

• Mechanism: Binds to HER2 (binds to a different HER2 epitope than trastuzumab)
• Dosing: 840 mg IV × 1, then 420 mg every 3 wks
• PK/PD: T1/2 ∼18 d
• AEs: Cardiotoxicity, HSR, diarrhea, leukopenia, neutropenia
• DDI: No known pathways of metabolism